-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces FDA Accepts sNDA to Expand Use of VOXZOGO for Injection to Treat Children with Achondroplasia Under the Age of 5
-
-
-
-
-
-
-
BioMarin (BMRN) PT Raised to $200 at BofA Securities, Added to US 1 List
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Sells Priority Review Voucher for $110 Million
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) Likely to Get EU Approval of Voxzogo in Next 10 Days, Opening a $4.4B Opportunity - Cowen
-
-
-
-
-
-
-
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and P
-
-
-
-
-
-
-
BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Highlights 4-Yrs of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia
-
12,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All